- page

Domain Therapeutics appoints Sean A. MacDonald as Chief Executive Officer

Domain Therapeutics to participate at premier investor and healthcare conferences

Domain Therapeutics to present latest data on DT-9045, a first-in-class Negative Allosteric Modulat...

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 ...

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

Domain Therapeutics further strengthens leadership team with appointment of Sean A. MacDonald as Ch...

Domain Therapeutics awarded Hospital-University Research in Health (RHU) SPRINT consortium grant to ...

Domain Therapeutics strengthens leadership team to spearhead global development and North American e...

Domain Therapeutics announces the European Patent Office decision to grant a patent for its propriet...

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further ...